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ABSTRACT
There are significant differences between the incidence of gastrointestinal (GI) symptoms
between males and females. A recent review found that females report having more severe GI
health problems compared to males. One explanation for the higher reporting rates of GI
symptoms in females could be attributed to menstrual cycle influences rather than GI processes.
This research aims to examine the relationship between how gastrointestinal (GI)
symptoms experienced by women covary with the different stages of the menstrual cycle. A
secondary purpose is to determine the moderating effect of health anxiety on the severity of
menstrual and GI symptoms.
Responses were collected and analyzed from 531 eligible participants using an
anonymous online survey. The survey encompassed the GI-PROMIS scales, Health Anxiety
Inventory, Pain Map, a Physiological profile assessment, and demographic items. Participants
were placed into one of three groups relating to their phase in the menstrual cycle.
It was hypothesized that higher GI symptom levels and higher belly pain ratings would be
observed during the Menstrual and Luteal groups compared to the Follicular groups. These
differences will be observed after controlling for levels of health anxiety. Individuals with
greater menstrual and premenstrual symptoms are hypothesized to indicate increased pain in the
Hypogastric region, which includes the female reproductive organs.
There were no significant multivariate differences between the groups on the GI
PROMIS scales or the Pain Map, which indicates that when these variables were used together,
they did not discriminate between the phases of menstrual cycle in healthy young women with
iii

regular 28-day periods. That the Menstrual group reported significantly higher Belly Pain scores
and higher Pain ratings at the hypogastric region (Region H) compared to the other two groups
suggests that increased GI PROMIS Belly Pain T-score elevations are likely to originate from the
hypogastric region (Region H) and are related to the menstrual cycle. Additionally, the results
showed that health anxiety is a significant moderating variable in women’s reporting of GI
symptoms and Pain ratings, which suggests a possible mechanism for the previously documented
sex differences in GI symptom reporting.
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INTRODUCTION
There are significant differences between the incidence of gastrointestinal (GI) symptoms
between males and females. A recent review found that females report having more severe GI
health problems compared to males (Vivier, 2019). However, no study has distinguished
between pain due to GI, menstrual, or general bodily symptoms in females. One explanation for
the higher reporting rates of GI symptoms in females could be attributed to menstrual cycle
influences rather than GI processes.

Sex Differences between Male and Female GI pain
For many chronic pain disorders, including Functional Gastrointestinal Disorders
(FGIDs), the prevalence is significantly higher in women than in men (Unruh, 1996).
Epidemiological evidence has shown that females are more likely than men to report symptoms
of pain of any duration and severity (Unruh, 1996). In fact, laboratory studies have shown that
when both men and women are exposed to the same experimental noxious stimuli (pressure and
electrical stimulation), females reported higher levels of pain (Fillingim and Maixner, 1995;
Berkley, 1997; Riley et al., 1998). A meta-analysis of pain studies showed that women were, on
average, more sensitive to pain and had less pain tolerance than men (Riley et al., 1998).
Irritable Bowel Syndrome (IBS) is a specific chronic pain condition with documented sex
differences. Up to twice as many females are affected compared to males (Drossman et al.,
2002). In one study that measured the development of post-infectious IBS after gastroenteritis,
females demonstrated a disproportionate development of IBS symptoms. Three months
1

following the gastroenteritis, 77% of females had developed IBS symptoms, such as abdominal
pain, bloating, and cramping, while only 36% of males had developed IBS (Gwee et al., 1999).
In a study that evaluated GI symptoms amongst young adults with an approximately 1:1 ratio of
males to females, the percentage of females that made up the population of mild and moderate
GI health groups were 77.1% and 84%, respectively (Vivier, 2019). However, it is interesting to
note that prior to puberty, boys’ and girls’ gastrointestinal disorders occur with similar
prevalence (Walker, 1999). Thus, one may postulate that the possible explanation for sex
differences in FGIDS is the psychological and biological changes associated with puberty. One
of the central changes during puberty for females is menarche and the emergence of a regular
menstrual cycle.
Not only are there sex-based differences in the prevalence of FGIDS, but there are also
differences in the variation of GI symptom patterns. In populations of women and men with
equal levels of IBS severity, chronicity, and psychological distress, women have greater
extraintestinal symptoms compared to men, such as chronic pain and headaches (Lee et al.,
1999). In a large survey of college students, women reported significantly more gastrointestinal
symptoms, such as abdominal pain and bloating, compared to men (Taub et al., 1995). In a
community sample of IBS patients, women reported more constipation, while men reported more
diarrhea (Talley, 1991).
Although sex-based differences in GI symptomology is evident, it is possible that
external psychosocial factors play a role in the disparity between sexes. These variables include
higher levels of health anxiety in females or possible willingness to disclose GI as well as other
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physical and emotional symptoms (Fillingim & Maixner, 1995). Lastly, there may be inherent
and subtle sex biases in the Rome criteria for diagnosis of FGIDs (Smith et al.,1991).

Physical Symptoms Associated with GI Health
The physical symptoms and diagnoses associated with gastrointestinal health have been
extensively researched. GI symptoms are caused by pathologies including gastroesophageal
reflux disease (GERD), gastritis, peptic ulcer disease, gastroenteritis, gastric and esophageal
cancer, functional dyspepsia, and diabetes mellitus (Wallander, 2007). In 1985, the physical
symptoms associated with IBS included abdominal pain, constipation, and diarrhea (Svedland,
1985) and it also was associated with symptoms of abdominal distension and hard stool
(Thompson, 1984). Another diagnostic category of great interest at that time was peptic ulcers.
Peptic ulcers were associated with symptoms of stomach pain, heartburn, belching, and nausea
(Sjoudin, 1985). In 1988, the first patient-subjective rating scale of gastrointestinal symptoms
was created for patients with IBS and peptic ulcer disease, titled the Gastrointestinal Symptom
Rating Scale (GSRS). This scale was created because, at the time, clinicians had relied solely on
pathophysiological symptoms while patient reports and symptom ratings were not emphasized
(Svedlund, 1988). GSRS included patient ratings of abdominal pains, heartburn, acid
regurgitation, sucking sensations in the epigastrium, nausea, vomiting, borborygmus, abdominal
distension, eructation, increased flatus, decreased passage of stools, increased passage of stools,
loose stools, hard stools, and urgent need for defecation (Svedlund, 1988).
Traditionally, theories of GI disorders hypothesized that symptoms occur due to
abnormal functioning of the GI tract rather than structural or biochemical issues, so symptoms
3

can go undetected in medical tests. More recently, theories recognize a more complex picture
leading to the development of the construct of Functional Gastrointestinal Disorders (FGIDs).
FGIDs are disorders of the gut-brain axis characterized by a variety of recurring GI symptoms.
Symptoms may be caused by a combination of the following factors: motility disturbance,
visceral hypersensitivity, altered mucosal and immune function, altered gut microbiota, and
altered central nervous system processing. (Drossman, 2016, p. 1268). FGIDs affect all parts of
the GI tract. Accordingly, they are broken down into categories for disorders of the esophagus,
stomach, duodenum, bowels, gallbladder, sphincter of Oddi, anus, and rectum. There are over 30
FGIDs; however, the most common FGIDS include Irritable Bowel Syndrome (IBS), functional
dyspepsia, and functional abdominal pain. FGIDs are diagnosed based on the presence of
symptoms, using the Rome IV Criteria (Schmulson & Drossman, 2017).
In 1994, The Rome Foundation made the first effort to create a comprehensive diagnostic
and classification tool for all the FGIDs, by publishing the Rome I criteria. Rome criteria is
notable for shifting the FGID diagnostic methods from physiologically-based to symptom-based.
Rome criteria classified all FGIDs into six domains based on primary symptom types and
severity (Refer to Table 1).
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Table 1: FGID Domains According to the Rome IV Criteria

FGID Domains

Primary Symptoms

1. Esophageal Disorders

Heartburn, chest pain, or reflex

2. Gastroduodenal Disorders

Dyspepsia, belching, nausea/vomiting

3. Bowel Disorders

Constipation, diarrhea, gas/bloating

4. Centrally Mediated Disorders of GI Pain Abdominal pain
5. Gallbladder and Sphincter of Oddi

Sudden pain usually experienced during

Disorders

gallstone or gallbladder attacks

6. Anorectal Disorders

Fecal incontinence and anorectal pain

Note. (Drossman, 2016)

The Rome criteria has evolved over the years. Most recently, in 2016, the Rome IV
criteria was published. A notable change in the Rome IV was shifting away from the use of the
term “FGID” and instead referring to FGIDs as Disorders of Gut-Brain Interaction (DGBI)
(Schmulson & Drossman, 2017). This change in terminology was made to reflect the research
indicating the existence of bidirectional communication between the gut and the brain.
In the late 1970s, epidemiological researchers discovered the importance of evaluating
psychological and social factors in relation to biological factors when determining the etiology of
illnesses and predicting illness behaviors. This eventually became known as the biopsychosocial
model of illness. This played out in the context of GI health as well. Researchers discovered
there was a significant comorbidity of GI symptoms with psychological distress in both clinical
and non-clinical populations. For example, in studies investigating IBS patients receiving
treatment and non-clinical IBS patients, researchers found that higher levels of psychosocial
distress enabled symptom severity and illness behaviors (Drossman, 1988; Whitehead et al.,
5

1988). Stress can cause changes in the gut flora and affect the bidirectional communication
between the central nervous system and the gut (De Palma et al., 2014; Mayer et al., 2015). This
stress can induce bloating, gas, and discomfort (Carabotti et al., 2015).
Conducting a formal assessment of specific GI symptoms helps to gain accuracy, so the
National Institute of Health (NIH) created the PROMIS-Gastrointestinal Symptom Scales; these
scales are patient-reported outcomes on the severity of each unique gastrointestinal symptom.
These include scales on Belly Pain, Bowel Incontinence, Constipation, Diarrhea, Disrupted
Swallowing, Gas and Bloating, Nausea and Vomiting, and Reflux.
In summary, the physical symptoms and psychosocial factors associated with GI
disorders have been thoroughly studied since the 1970s and numerous assessment and diagnostic
tools have been constructed. The construct of DGBIs was developed to accurately study GI
symptoms, and the continuously evolving development of the Rome criteria has been offered as
a more effective and reliable diagnostic approach.

Physical Symptoms Associated with the Menstrual Cycle
Decades of research on the physical symptoms related to the menstrual cycle have helped
to establish common patterns of menstrual-cycle-related physiological changes (Kiesner et al.,
2016). The menstrual cycle encompasses both somatic and affective symptoms (Negriff et al.,
2009). Historically, clusters of menstrual cycle symptoms have been diagnosed as dysmenorrhea
(pain) and premenstrual syndrome (PMS) (Negriff et al., 2009).
Menstruation is the discharge of blood from the uterine lining that is regulated by
hormone levels, such as progesterone, luteinizing hormone, and follicle-stimulating hormone on
6

a cyclic basis. The cycle is made up of three main phases: the follicular phase, ovulatory phase,
and luteal phase, in that sequence specifically. The follicular phase is subdivided into the menses
and the proliferative period. The median length of a menstrual cycle is 28 days, while most
females’ cycles range from 25 to 30 days (Reed & Carr, 2018). The variability in the cycle
lengths is due to varying lengths of the follicular phase, which can range from 10 - 16 days
(Reed & Carr, 2018). The luteal phase, on the other hand, maintains a constant length of 14 days
in almost all women (Reed & Carr, 2018).
A series of studies surveyed women about their menstrual cycle, providing important
insight into the relationship between changes in the menstrual cycle and associated physical
symptoms. Research has shown that cognitive, affective, and physical symptoms fluctuate
according to the phases of the menstrual cycle (Ross & Coleman & Stojanovska, 2003; Van de
Akker, 1985). However, there are inconclusive findings about the pattern of symptom changes
through the stages of the menstrual cycle.
In a study by Ross, Coleman, and Stojanovska (2003), 181 women from the general
population, with a mean age of 30, completed a modified Menstrual Distress Questionnaire
survey every day for 70 days. The symptom subscales included negative affect, cognitive
symptoms, behavior changes, somatic symptoms, autonomic reactions, and fluid retention. Only
the subscales of somatic symptoms, fluid retention, and negative affect showed cyclicity, while
the subscales for behavior change, cognitive symptoms, and autonomic reactions were not
consistent. All symptoms were generally at their lowest level during the follicular phase and
increased premenstrually, with the greatest change occurring during the premenstrual period.
Symptom severity did not change significantly between the premenstrual period and menses.
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However, somatic symptoms were significantly higher in the menstrual phase compared to the
premenstrual phase, while fluid retention was higher premenstrually.
In another study by Van de Akker and Steptoelo (1985), 185 women completed a
modified version of the Menstrual Distress Questionnaire (MDQ) every day for 35 days. The
women were employees and students at a medical school and hospital, with ages ranging from 16
to 35. The mean age was about 23. Results showed that most symptoms peaked menstrually,
with the exceptions of weight gain, cold sweats, depression and painful breasts, which all peaked
premenstrually. Boyle and Grant’s (1992) study utilized the MDQ to survey symptoms from 103
young women and found that symptoms of pain, autonomic reaction, fluid retention, and
behavior changes peaked menstrually rather than premenstrually. On the other hand, negative
affect was highest premenstrually.

GI Symptoms Associated with the Menstrual Cycle
Only two studies were found which examined the relationship between specific GI
symptoms and the menstrual cycle. The first of these was Bernstein et al. (2012), who conducted
a study where 268 women with Inflammatory Bowel Disease (IBD) were compared with a
healthy cohort of women after completing a retrospective survey on their GI symptoms. They
concluded that perimenstrual GI symptoms were common in both healthy women and women
with IBD, indicating that GI symptoms vary uniquely with the menstrual cycle phases.
Bernstein et al. (2014) conducted a retrospective study surveying 156 healthy women
(Mean age: 32.3) on their emotional and GI symptoms over their past three menstrual cycles. A
unique questionnaire was developed to assess the range of GI symptoms and emotional
8

symptoms. The survey assessed seven GI symptoms specifically: abdominal pain, diarrhea,
constipation, nausea, vomiting, bloating, and pelvic pain. Of these participants, 73% experienced
at least one GI symptom in the premenstrual phase, while 69% reported at least one GI symptom
in the menstrual phase. Abdominal pain, diarrhea, and bloating were the most commonly
experienced GI symptoms. Overall, the prevalence of each GI symptom was similar across both
phases. The authors concluded that more research is needed to precisely “quantify the prevalence
or nature of these symptoms, or to consider associated factors,” (Bernstein et al., 2014).
However, the studies that did focus on the relationship between GI symptoms and menses
investigated only an incomplete range of GI symptoms or investigated individuals who had a
diagnosed GI disorder. Therefore, a limited amount of research has been done investigating how
the complete range of GI symptoms varies along the phases of the menstrual cycle in an
otherwise healthy cohort of women.
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PURPOSE STATEMENT
The objective of this study was to examine the relationship between gastrointestinal (GI)
symptoms experienced by women during different stages of the menstrual cycle. The menstrual
phase is defined by the 7-day period that a female is undergoing menses. The follicular phase is
defined as the seven days following the end of the menstrual phase. The luteal phase is defined
as the 14-day period starting after the end of the follicular phase.
Additionally, I examined the role of health anxiety as a moderating variable of GI
symptoms’ severity. This cross-sectional study collected information through an online survey
from a large population of undergraduate females. The following research questions were
answered: (1) Do GI symptoms occur more predominantly during a specific phase of the
menstrual cycle? (2) To what extent does health anxiety moderate the degree of GI symptoms?
By investigating the relationship between GI symptoms and the menstrual cycle, we hoped to
acquire a greater understanding of which specific GI symptoms are commonly associated with
each stage of the menstrual cycle. Investigating whether there is a relationship between health
anxiety and GI symptoms at a particular stage of the menstrual cycle (i.e., premenstrually and
during menses) may help explain why some women have more severe GI problems and
dysmenorrhea.
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HYPOTHESIS
Based on the literature review, the primary hypothesis was that there would be higher GI
symptoms as measured by the PROMIS-GI scales during the menstrual and luteal phases of the
menstrual cycle compared to the follicular phase. Women were assigned to one of three groups.
Their average level of symptoms on PROMIS-GI were compared. It was predicted that women
in the luteal phase would demonstrate higher GI and belly pain symptoms. Health anxiety was
included in the analyses as a covariate to examine whether it is a significant moderator in this
relationship. I hypothesized that higher levels of health anxiety will be associated with higher GI
symptom severity, higher belly pain scale scores, and increased intensity of symptoms
throughout all the phases of the menstrual cycle.
Exploratory analyses examined intercorrelations between the different dependent
measures. Individuals that have higher GI symptom severity were hypothesized to have higher
belly pain reporting across the entire abdomen region. Individuals that reported greater menstrual
and premenstrual symptoms were hypothesized to indicate increased pain in the Hypogastric
region, which includes the female reproductive organs.
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METHODS
The online survey included 131 questions assessing FGID symptoms and health anxiety.
The survey also included demographic items such as age, gender, race, and ethnicity.
Additionally, there was a physical assessment of participants’ typical menstrual cycle patterns.
The survey took about 30 minutes to complete. Two validity check questions were also included
in the questionnaire as a determining variable for respondent data elimination or retention. The
data analysis for this paper was generated using Qualtrics software (Qualtrics, Provo, UT).

Functional Gastrointestinal Assessment
The NIH PROMIS-GI symptom scales. The National Institutes of Health (NIH)
developed the Patient Reported Outcomes Measurement Information System (PROMIS®)
Gastrointestinal Symptom Scales (PROMIS-GI) in 2014. The PROMIS-GI scales have been
validated as an effective measure of a broad range of GI symptoms within the general and
clinical populations. (Shah, Almario, Speigel, & Chey, 2018; Spiegel et al., 2014). The
PROMIS-GI symptom scales may be effective in identifying clinical thresholds for action
(Spiegel et al., 2014). The PROMIS-GI scales have been concluded to have good psychometric
measures, such as internal construct validity (Spiegel et al., 2014). The PROMIS-GI scales
evaluate eight GI symptom domains: abdominal pain (6 items), gas/bloating (12 items), diarrhea
(5 items), constipation (9 items), bowel incontinence (4 items), gastroesophageal reflux (GER)
(13 items), disrupted swallowing (8 items), and nausea/vomiting (4 items). Scores will be
calculated by pre-determined algorithms available via the PROMIS website. Individuals’ scores
are provided as a T-score metric. The higher the T-score, the greater the severity of the symptom.
12

T-scores will be converted into GI symptom severity levels using the suggested general PROMIS
T-Score threshold range of mild (t-scores between 55 and 60), moderate (t-scores between 60
and 70), and severe (t-scores above 80).
Abdominal Pain Scale. The pain scale used here (refer to Figure 1) is an adaptation of
the numeric rating scale that is commonly used in many medical specialties (Williamson &
Hoggart, 2005). Individuals are asked to report their pain on a scale from 0 to 10, with 0
representing least pain and 10 representing the most pain possible. The abdominal regions were
graphically divided into nine regions and individuals provided a numeric rating for each region.
This was facilitated by a drawing of the abdomen with a 3 x 3 grid drawn on top of the image.
This will allow for differentiation of different types of belly pain: menstrual cramps or
gastrointestinal issue.

Figure 1: Abdominal Pain Scale
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The abdomen can be divided into nine regions for purposes of clinical research and practice.
Table 2 below provides details on the medical terminology and associated organs for each region
in the Abdominal Pain drawing.
Table 2: Identification of 9 Clinical Subdivisions of the Abdominal Region

Region

Location

Included Organs

A

Right
Hypochondriac

Upper row, right

Liver, Gallbladder, Right Kidney, Small
Intestine

B

Epigastric

Upper row, middle

Stomach, Liver, Pancreas, Duodenum,
Spleen, Adrenal Glands

C

Left Hypochondriac

Upper row, left

Spleen, Colon, Left Kidney, Pancreas

D

Right Lumbar

Middle row, right

Gallbladder, Liver, Right Colon

E

Umbilical Region

Center

Umbilicus, Jejunum, Ileum, Duodenum

F

Left Lumbar

Middle row, left

Descending Colon, Left Kidney

G

Right Iliac

Lower row, right

Appendix, Cecum

H

Hypogastric Region

Lower row, middle

Urinary Bladder, Sigmoid Colon, Female
Reproductive Organs

I

Left Iliac

Lower row, left

Descending Colon, Sigmoid Colon

Health Anxiety Assessment
Short Health Anxiety Inventory. The Health Anxiety Inventory was developed in 2002
in order to measure healthy anxiety and the cognitive factors associated with hypochondriasis
independent of physical health status (Abramowitz, Deacon, & Valentiner, 2007). The original
14

Health Anxiety Inventory has 64 items, with each item on a four-point Likert scale (Solkovskis
et al., 2002). An abbreviated 18-item scale was also constructed, termed the Short Health
Anxiety Inventory (SHAI) (Solkovskis et al., 2002). There are three factors in the SHAI that
assess the perceived likelihood of becoming ill, body vigilance, and the perceived severity of
becoming ill (Abramowitz, Deacon, & Valentiner, 2007). The SHAI is often preferred in
research and clinical settings because it has comparable validity and reliability to the original
Health Anxiety inventory (Abramowitz, Deacon, & Valentiner, 2007). The SHAI was
determined to have good psychometric properties, including reliability and convergent,
divergent, predictive, construct, and criterion validity (Abramowitz, Deacon, & Valentiner,
2007). The first 14 items on the SHAI represent the main section of the SHAI (Solkovskis et al.,
2002). Each item is scored on a scale of 0 – 3 and the items are totaled to create a score
(Solkovskis et al., 2002). For the purpose of this study, only the first 14 items of the SHAI were
used. Higher scores indicate higher levels of health anxiety (Solkovskis et al., 2002).

Demographic Assessment
Demographic information collected in this study included standard items, such as age,
gender, race/ethnicity, marital status, and college status. Additionally, a physiological profile
assessment was collected to assess the pattern of the menstrual cycle in each participant, such as
if and when GI symptoms occur in relation to their menstrual cycle, and if they have any
diagnosed conditions or contraceptive use.

15

Participants
Undergraduates enrolled in introductory psychology courses at a large, public university
in the southeastern United States were recruited to participate in this study for course credit.
Introductory psychology is a required course for all programs at this university, which ensures
that a diverse range of majors and backgrounds were represented in the undergraduate
population. Eligibility criteria excluded vulnerable populations and required participants to be
biologically female, between the ages of 18 and 25 years, and able to complete an online
questionnaire in the English language. All measures were administered online. This study was
approved by the Institutional Review Board of the university.
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PROCEDURE
Data was collected from June 22, 2020 until December 3, 2020. Participants completed
the survey by logging into SONA, an online research system in which students can participate in
research studies in order to receive course credit while remaining anonymous to the researcher.
SONA connects participants to the Qualtrics surveys and stores their responses. The study closed
after 717 individuals responded to the survey.

Data Cleaning
The dataset was reviewed prior to data analysis. Participants were removed using the
following exclusion criteria:
1. Report of last period starting more than 28 days prior which indicates an irregular cycle
(n = 146).
2. Endorsement of one or more validity check item (n = 15).
3. Failure to complete survey (n = 18).
4. Outside 18 - 25 age range (n = 1).
5. Inconsistent reporting regarding their period start and end dates (n = 6).
6. Pregnancy (n = 0).
Additionally, mean substitution was utilized to fill in missing responses for 25
participants on the GI-PROMIS Gas and Bloating T-scores, two participants on the Pain MapRegion C, and one participant for the item “How much do you weigh, in pounds?” After these
steps for data cleaning, the final sample size was 531 participants.
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Group Assignment
Participants were then categorized into one of three groups based on their answer to the
survey question, "How many days ago did your most recent period start?" If they answered “0 - 7
days ago”, they were operationally defined as in the Menstrual group. If the participant answered
“8 - 14 days ago” they were assigned to the Follicular group. If the response was “15 - 28 days
ago”, they were assigned to the Luteal group. This group assignment was based on the traditional
phases of the menstrual cycle as described by Fehring, Schneider, and Raviele (2006).

Participant Demographics
Using the criteria described above to classify participants into one of three groups, the
Menstrual group totaled 126 participants, the Follicular group had 150 participants, and the
Luteal group represented 255 women.
The average age of the participants was 19.1 years, SD = 1.6 years. The average BMI of
the participants was 23.8 kg/m2, SD = 5.1 kg/m2. There were no significant differences between
the groups on these two variables. There was a diverse spread of participants across race and
college status. Ninety-eight percent of the women were not married. The demographic
descriptions for each group are listed in Table 3 below. A chi-square analysis revealed no
significant differences between the three groups of participants on any categorical variable.
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Table 3: Participants' gender, race, marital status, and college status by Group

Variables

Menstrual (N=126)

Follicular (N=150)

Luteal (N=255)

N
%
N
%
N
Race*
White
78
14.7
79
14.9
133
Black
15
2.8
26
4.9
42
Hispanic/Latino
25
4.7
51
9.6
77
Asian/Pacific
12
2.3
14
2.6
21
Islander
Native American
1
0.2
0
0
2
Other
5
0.9
6
1.1
14
Marital status
Not married
124
23.4
147
27.7
251
Married
2
0.4
3
0.6
4
College status
Freshman
76
14.3
88
16.6
156
Sophomore
20
3.8
23
4.3
32
Junior
16
3.0
19
3.6
40
Senior
14
2.6
19
3.6
27
Unclassified
0
0
1
0.2
0
* Race frequency values are not additive because participants selected multiple racial
identifications
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%
25.0
7.9
14.5
4.0
0.4
2.6
47.3
0.8
29.4
6.0
7.5
5.1
0

RESULTS
All statistical analyses were conducted on SPSS version 26. Means and standard
deviations for the measures are presented by group in Table 4.
Table 4: Mean and Standard Deviations of GI PROMIS scales by Group

GI-PROMIS Measure

Belly Pain
Nausea
Diarrhea
Constipation
Gas
Swallow
Reflux

Menstrual (N=126)
Mean
SD

Follicular (N=150)
Mean
SD

Luteal (N=255)
Mean
SD

55.452
53.192
46.796
49.572
55.944
48.063
45.074

53.473
51.203
46.428
49.228
54.840
46.625
44.367

52.794
51.875
46.287
49.938
54.829
47.496
45.515

9.891
8.750
7.555
7.771
5.851
7.123
8.071

9.484
8.413
8.006
7.619
7.508
6.023
6.834

10.322
8.581
7.268
7.301
6.912
6.544
7.245

A MANCOVA was conducted on the seven GI PROMIS scales with the three Menstrual
groups as a fixed factor and the SHAI score as a covariate. No significant multivariate main
effect for group was obtained, indicating that the GI PROMIS measures were not significantly
distinguishable between the three groups. However, a significant multivariate main effect was
obtained for the SHAI covariate (F (7, 521) = 17.830, p = 0.000, Pillai’s V = .193, partial η2 =
.193, power = 1.0), which demonstrates that the SHAI scores had a significant effect on the GI
PROMIS scores across all three groups.
Next, the tests of between-subjects effects were reviewed for the seven GI PROMIS
subscales with the three groups as a fixed factor and the SHAI scores as a covariate. These were
planned comparisons since differences between the groups on the GI PROMIS Scales was a
central purpose of this study. The Belly Pain GI subscale demonstrated a significant difference
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between the three groups (F (2, 527) = 3.253, p = 0.039, partial η2 = 0.012, power = .619).
Further planned comparisons revealed that there was a significant difference between the
Menstrual and Luteal groups on the GI PROMIS Belly pain scores (p = 0.012). Review of Table
4 indicates that the Menstrual group had higher GI PROMIS Belly Pain than the Luteal group.
No other contrasts were significant.
The SHAI scores were a significant covariate for each of the seven PROMIS GI scales,
illustrated in Table 5. This indicates that SHAI was a significant moderator for women’s
reporting of their GI pain symptoms across all seven PROMIS GI subscales. Additionally, a
Bivariate correlation test was performed to indicate the direction and strength of the relationship
between SHAI scores and GI PROMIS scale T-scores. This is demonstrated in Table 6.

Table 5: SHAI covariance with the GI PROMIS scale T-Scores

GI PROMIS
T-Scores
By Scale

Type III
Sum of
Squares

Belly Pain

Sig.

Partial
Eta
Squared

Observed
Power

54.435

.000

.094

1.000

2093.915

39.916

.000

.070

1.000

1

1496.953

27.577

.000

.050

.999

2006.957

1

2006.957

46.381

.000

.081

1.000

Nausea

3961.603

1

3961.603

59.888

.000

.102

1.000

Swallow

1210.341

1

1210.341

29.789

.000

.054

1.000

Reflux

3515.397

1

3515.397

74.346

.000

.124

1.000

df

Mean
Square

F

4933.329

1

4933.329

Constipation

2093.915

1

Diarrhea

1496.953

Gas and
Bloating
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Table 6: SHAI correlation with the GI PROMIS scale T-Scores

Pearson
Correlation
Sig.
(2-tailed)

Belly Pain
T score

Constipation
T score

Diarrhea
T score

Gas T
score

Nausea
T score

Swallow Reflux
T score T Score

.305

.264

.223

.284

.317

.229

.350

.000

.000

.000

.000

.000

.000

.000

Next, I turned to the analysis of the Pain Map by group. The means and standard
deviations for the nine pain ratings are presented by group in Table 7.

Table 7: Mean and Standard Deviations of Pain Map regions by Group

A – Right Hypochondriac
B – Epigastric

Menstrual (N=126)
Mean
SD
0.587
1.161
1.016
1.711

Follicular (N=150)
Mean
SD
0.827
1.574
1.040
1.806

Luteal (N=255)
Mean
SD
0.839
1.705
1.231
2.138

C – Left Hypochondriac
D – Right Lumbar
E – Umbilical Region
F – Left Lumbar
G – Right Iliac
H – Hypogastric
I – Left Iliac

0.714
1.262
2.333
1.397
2.460
4.198
2.413

0.691
1.300
2.393
1.260
1.987
3.687
1.900

0.830
1.228
2.373
1.322
1.929
3.094
1.859

Pain Map Region

1.528
1.911
2.626
2.016
2.957
3.145
2.935

1.331
2.154
2.664
2.128
2.642
3.028
2.564

1.683
2.039
2.751
2.098
2.733
3.153
2.721

A MANCOVA was performed using the nine ratings from the Pain Map with the three
groups as a fixed factor and the SHAI score as a covariate. No significant multivariate effect was
obtained by group, which indicates that the Pain Map ratings were not significantly affected by
the three groups. However, a significant multivariate effect was obtained for the SHAI covariate
(F (9, 519) = 5.253, p = .000, Pillai’s V = .083, partial η2 = .083, power = 1.0), which
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demonstrates that the SHAI scores had a significant effect on the Pain Map ratings across all
three groups.
Next, the tests of between-subjects effects as planned comparisons were reviewed for the
nine Pain Map regions with the three groups as a fixed factor and the SHAI scores as a covariate.
The Pain Map rating for Region H demonstrated a significant difference between the three
groups (F (2, 527) = 5.679, p = 0.004, partial η2 = 0.021, power = .862). Further planned
comparisons revealed that there was a significant difference between the Menstrual and Luteal
groups on the Pain Map ratings for Region H (p = 0.001). Review of Table 7 indicates that the
Menstrual group had higher Pain rating at the hypogastric (Region H) compared to the Luteal
group. No other contrasts were significant.
The SHAI scores were a significant covariate for each of the 9 Pain Map regions as
illustrated in Table 8. This indicates that SHAI was a significant moderator for women’s
reporting of their belly pain severity across all nine belly pain map regions. Additionally, a
Bivariate correlation test was performed to indicate the direction and strength of the relationship
between SHAI scores and the Pain Map region scores. This is demonstrated in Table 9 below.
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Table 8: SHAI covariance with the Pain Map Region Scores

Pain Map by Region

Type III
Sum of
Squares

df

Mean
Square

F

Sig.

Partial
Eta
Squared

Observed
Power

A – Right Hypochondriac

16.534

1

16.534

6.916

.009

.013

.747

B – Epigastric

65.908

1

65.908

17.838

.000

.033

.988

C – Left Hypochondriac

35.749

1

35.749

15.200

.000

.028

.973

D – Right Lumbar

41.140

1

41.140

10.030

.002

.019

.885

E – Umbilical Region

189.170

1

189.170

27.296

.000

.049

.999

F – Left Lumbar

33.888

1

33.888

7.879

.005

.015

.800

G – Right Iliac

126.031

1

126.031

17.013

.000

.031

.985

H – Hypogastric

228.074

1

228.074

24.530

.000

.044

.999

I – Left Iliac

119.873

1

119.873

16.550

.000

.030

.982

Table 9: SHAI correlation with the Pain Map Region Scores

Pearson
Correlation
Sig.
(2-tailed)

A

B

C

D

E

F

G

H

I

.114

.180

.167

.137

.222

.121

.176

.210

.174

.009

.000

.000

.002

.000

.005

.000

.000

.000

Exploratory analyses were conducted comparing participants who reported having
received a medical FGID diagnoses with those who did not. This was conducted on all
participants without regard to whether they had reported a period starting in the last 28 days.
This resulted in a total of 677 participants who were assigned to a FGID group or Non-FGID
group. Women who self-reported a diagnosis of IBS, Crohn’s Disease, IBD, or Ulcerative Colitis
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were placed in the FGID group (n = 31) and the remaining women were placed in the non-FGID
group (n = 646).
The means and standard deviations for the GI-PROMIS measures are presented by FGID
group in Table 10.
Table 10: Mean and Standard Deviations of GI PROMIS scales by Group (FGID and Non-FGID)

FGID (N=31)
Mean
SD

Non-FGID (N=646)
Mean
SD

62.116
53.548
51.197
55.826
59.716
48.868
49.868

53.176
51.924
46.005
49.595
54.886
47.375
44.743

GI-PROMIS Measure

Belly Pain
Nausea
Diarrhea
Constipation
Gas
Swallow
Reflux

8.531
8.624
8.584
6.630
6.867
6.465
8.472

9.8986
8.501
7.393
7.393
6.847
6.615
7.210

A MANCOVA was conducted on the seven GI PROMIS scales with the two groups
(FGID and Non-FGID) as a fixed factor and the SHAI score as a covariate. There was a
significant multivariate main effect for group (F (7, 668) = 5.054, p = 0.000, Pillai’s V = .050,
partial η2 = .050, power = 0.997). This indicates that the GI PROMIS scales were able to
discriminate between participants with FGIDS and without FGIDS. A significant multivariate
main effect was also obtained for the SHAI covariate (F (7, 668) = 22.368, p = 0.000, Pillai’s V
= .190, partial η2 = .190, power = 1.0).
The tests of between-subjects effects were reviewed for the seven GI PROMIS subscales
with the two groups (FGID and Non-FGID) as a fixed factor and the SHAI scores as a covariate.
Five of the seven GI PROMIS subscales demonstrated significant differences between groups:
Belly Pain, Constipation, Diarrhea, Gas, and Reflux. The values are shown in Table 11 below.
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For these five GI PROMIS subscales, the FGID group reported higher symptom severity scores
compared to the non-FGID groups, as seen in Table 10.
Table 11: Main Effect of Group (FGID and Non-FGID) on Individual GI PROMIS scale T-Scores

GI PROMIS
T-Scores
By Scale

Type III
Sum of
Squares

df

Mean
Square

F

Sig.

Partial
Eta
Squared

Observed
Power

Belly Pain

1446.630

1

1446.630

16.167

.000

.023

.980

Constipation

708.798

1

708.798

13.972

.000

.020

.962

Diarrhea

477.813

1

477.813

9.042

.003

.013

.851

Gas and
Bloating

367.821

1

367.821

8.451

.004

.012

.827

Reflux

329.547

1

329.547

7.106

.008

.010

.759

The SHAI scores were a significant covariate for each of the seven PROMIS GI scales
and FGID group, as illustrated in Table 12. This demonstrates that SHAI was a significant
moderator for women of both the FGID and non-FGID groups in the reporting of their GI pain
symptoms across all seven PROMIS GI subscales.

26

Table 12: SHAI covariance with the GI PROMIS scale T-scores & Group (FGID and Non-FGID)

GI PROMIS
T-Scores
By Scale

Type III
Sum of
Squares

Belly Pain

Sig.

Partial
Eta
Squared

Observed
Power

56.683

.000

.078

1.000

2382.801

46.969

.000

.065

1.000

1

1845.145

34.917

.000

.049

1.000

2316.240

1

2316.240

53.216

.000

.073

1.000

Nausea

4655.639

1

4655.639

71.009

.000

.095

1.000

Swallow

1749.974

1

1749.974

42.540

.000

.059

1.000

Reflux

4428.838

1

4428.838

95.497

.000

.124

1.000

df

Mean
Square

F

5072.056

1

5072.056

Constipation

2382.801

1

Diarrhea

1845.145

Gas and
Bloating

In addition, I analyzed the difference in Pain Map scores by group (FGID and NonFGID). The means and standard deviations for the 9 pain regions are presented by group in Table
13.
Table 13: Mean and Standard Deviations of Pain Map regions by Group (FGID and Non-FGID)

Pain Map Region
A – Right Hypochondriac
B – Epigastric
C – Left Hypochondriac
D – Right Lumbar
E – Umbilical Region
F – Left Lumbar
G – Right Iliac
H – Hypogastric
I – Left Iliac

FGID (N=31)
Mean
SD
1.065
2.081
2.097
3.113

No FGID (N=646)
Mean
SD
0.728
1.515
1.014
1.807

0.960
1.355
4.871
1.903
2.484
5.161
3.000

0.744
1.201
2.195
1.269
2.077
3.435
2.011

2.121
2.138
2.790
2.599
2.839
2.782
3.141
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1.536
2.028
2.612
2.086
2.784
3.170
2.759

A MANCOVA was performed using the 9 ratings from the Pain Map with the two FGID
groups as a fixed factor and the SHAI score as a covariate. There was a significant multivariate
effect obtained by FGID group (F (9, 666) = 4.378, p = .000, Pillai’s V = .056, partial η2 = .056,
power = .998). Also, there was a significant multivariate effect obtained for the SHAI covariate
(F (9, 666) = 6.360, p = .000, Pillai’s V = .079, partial η2 = .079, power = 1.0).
The test of between-subjects effects for the 9 pain map regions and the FGID groups
demonstrated that there is a significant difference in regions B, E, and H. The values are listed in
Table 14. The results indicate that the FGID group experienced more pain in the Epigastric
region (Region B), Umbilical region (Region E), and Hypogastric region (Region H) compared
to the non-FGID group.

Table 14: Main Effect of Group (FGID and Non-FGID) on Pain Region Ratings

Type III
Sum of
Squares

df

Mean
Square

F

Sig.

Partial
Eta
Squared

Observed
Power

B – Epigastric

21.747

1

21.747

6.291

.012

.009

.707

E – Umbilical Region

156.652

1

156.652

23.699

.000

.034

.998

H – Hypogastric

47.020

1

47.020

4.938

.027

.007

.602

Pain Map
By Region

The SHAI scores were a significant covariate for every individual region on the Pain
Map. This is shown in Table 15 below. This demonstrates that health anxiety was a significant
moderator for women of both the FGID and non-FGID groups in the reporting of their belly pain
severities across all nine belly pain regions.

28

Table 15: SHAI covariance with the Pain Map Region Scores

Pain Map by Region

Type III
Sum of
Squares

df

Mean
Square

F

Sig.

Partial
Eta
Squared

Observed
Power

A – Right Hypochondriac

13.914

1

13.914

5.876

.016

.009

.677

B – Epigastric

67.662

1

67.662

19.573

.000

.028

.993

C – Left Hypochondriac

45.361

1

45.361

18.984

.000

.027

.992

D – Right Lumbar

55.047

1

55.047

13.571

.000

.020

.957

E – Umbilical Region

177.756

1

177.756

26.892

.000

.038

.999

F – Left Lumbar

68.334

1

68.334

15.658

.000

.023

.977

G – Right Iliac

125.347

1

125.347

16.523

.000

.024

.982

H – Hypogastric

295.347

1

295.347

31.018

.000

.044

1.000

I – Left Iliac

126.408

1

126.408

16.770

.000

.024

.983
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DISCUSSION
A review of the literature on the assessment of patient-reported outcomes consistently
finds that women report higher levels of GI symptoms than men. Men and women differ on
many biopsychosocial variables. One of the most prominent is that women experience hormonal
changes in relation to their menstrual cycle. This study asks the question of whether the higher
levels of GI symptoms experienced by women may be related to the different stages of the
menstrual cycle. A relatively new clinical instrument, the GI PROMIS Scales were used to assess
the broad range of gastrointestinal functioning in our participants. In addition, a Pain Map was
used so that participants could precisely identify the regions of the abdomen where they
experience pain.
Prior to analysis, participants were initially categorized into one of three groups based on
the menstrual phase they reported. They were placed into a Menstrual group if they were in the
7-day window that the woman reported menstruating, the Follicular group if they were in the 7day period following the end of the menstruation, and the Luteal group if they reported they were
in the 14-day period following their follicular phase.
Given the literature review, it was hypothesized that there would be higher GI symptoms
in the Menstrual group and Luteal group versus the Follicular group. However, this hypothesis
was not supported because no significant multivariate differences between the groups on the GI
PROMIS scales or the Pain Map were observed. This means that when these variables were
considered together, they did not discriminate between the phases of menstrual cycle in healthy
young women with regular 28-day periods. However, a significant difference between the
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Menstrual and Luteal groups was observed on selected pain measures in the planned
comparisons. The Menstrual group reported higher Belly Pain T scores compared to the Luteal
group. This was the only difference between the groups on any GI PROMIS scale.
This difference may be explained in part by a review of the Pain Map analyses, which
found that women in the Menstrual group reported significantly higher pain in the hypogastric
region (Region H) compared to women in the Luteal group. The hypogastric region is associated
with the female reproductive organs that are most often implicated in menstrual pain. With these
two findings in mind, one can infer that the increased GI PROMIS Belly Pain T score elevations
are likely to originate from the hypogastric region (Region H) and are related to the menstrual
cycle. Fortunately, these symptoms are easily discriminated from other significant GI symptoms
because of their specific location and periodicity.
Thus, only minor differences in the GI PROMIS scales were observed across groups.
Furthermore, the influence of the menstrual cycle on these measures was easy to discriminate
from gastrointestinal symptoms and probably pain due to menstrual cramping. These results
demonstrate that except for one GI PROMIS score – Belly Pain, the GI PROMIS subscales did
not vary significantly with the phases of the menstrual cycle. Taken together, the findings
indicate that the PROMIS GI scales appear to be relatively unaffected by physical symptoms
arising from the menstrual cycle in women.
A secondary hypothesis was that health anxiety would be significantly correlated with
higher GI PROMIS symptom severity and higher belly pain scores across all the phases of the
menstrual cycle. The statistical analyses showed that all the PROMIS GI scales, as well as all the
Pain map regions, covaried significantly with the Short Health Anxiety Inventory, as evidenced
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by Tables 5 and 8. This indicates that health anxiety is a significant moderating variable in
women reporting of GI symptoms and Pain ratings, suggesting a possible mechanism for the
previously documented sex differences in GI symptom reporting.
Additionally, the results of the exploratory analyses suggest that there are significant
differences between the FGID and non-FGID groups on the GI PROMIS scales and Pain Map
ratings, with FGID groups reporting more GI symptoms and greater Abdominal Pain
experienced. The FGID disorders encompass gastroduodenal disorders, bowel disorders, and
centrally mediated disorders, to name a few. The increased severity noted in the FGID group for
the Constipation, Diarrhea, and Gas subscales is attributed to bowel disorders. The increased
Belly Pain scores in the FGID groups in conjunction with the Pain Map analysis suggest that the
belly pain experienced from these FGID diagnoses is localized to the middle column of the
abdomen (epigastric region, umbilical region, and hypogastric region). These findings support
the utility of the GI PROMIS scales in the diagnoses of FGID disorders, because it is expected
that FGID groups will report significantly higher GI symptom severity compared to non-FGID
groups.

Limitations
One limitation of this study was that the classification of women into one of the three
menstrual phase groups was entirely based on women’s self-report of the start and end date of
their most recent period. This introduces the possibility of participant recall error. Another
limitation was that women were filtered out and placed into one of three groups assuming that
every woman had a 28-day menstrual cycle. Women were excluded from the study if they
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reported a period length greater than 28 days. This is a possible source of error because not all
women have a regular, 28-day menstrual cycle, so some participants may have been erroneously
excluded from data analyses, while some participants may have been placed into the wrong
group.

Clinical Implications
This study supports the utility of the GI PROMIS scales in assessing gastrointestinal
symptom severity, given that the results from this study showed that the GI PROMIS scales were
relatively unaffected by the physical symptoms arising during the different phases of the
menstrual cycle. The exploratory analyses yielded a significant difference between the FGID and
non-FGID groups on the GI-PROMIS scales, which further validates the use of the GI-PROMIS
scales in diagnosing FGIDs.
This study suggests that researchers and clinicians should factor in a woman’s menstrual
cycle when interpreting belly pain symptoms. The results showed that women in the menstrual
phase reported belly pain symptoms originating in the hypogastric region, suggesting that their
reported belly pain symptoms may be in part due to menstrual pain. Given that the GI PROMIS
Belly Pain scale does not provide specific location information, I encourage clinicians to utilize a
pain map diagram to further localize the regions of belly pain to distinguish between menstrual
cycle-related pain and GI pain.
The findings also highlight that health anxiety plays a significant role in the severity of
GI symptoms. Clinicians may consider factoring in health anxiety in the diagnosis and treatment
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of their patients. If necessary, clinicians can refer patients to the appropriate mental health
practitioners to help patients manage their health anxiety.

Future Directions
Several studies have been published suggesting women experience higher levels of health
anxiety. This suggests a possible mechanism for sex differences in GI symptom reporting. Future
work should therefore include health anxiety as a moderator in studies with men.
Given the cross-sectional design of this study, a more reliable marker of determining
women’s current menstrual phase would be optimal for future studies, such as obtaining blood
samples. Additionally, the cross-sectional design of this study did not facilitate any conclusions
to be made on the direction of GI symptom variations between the different menstrual cycle
phases. A future study may utilize longitudinal GI symptom reporting to address that.
These results may not be generalizable for women above the age 18-25, so this study
needs to be replicated with older women.
Despite the limitations of this study, this research provides the first investigation into
quantifying the associations of a full range of GI symptoms across the phases of the menstrual
cycle. The results of this study are that the GI symptoms do not vary significantly across the
phases of the menstrual cycle. In fact, the reporting of GI pain in women in any phase of the
menstrual cycle is highly influenced by health anxiety, which provides a possible explanation for
the sex-based differences in GI pain between men and women.
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APPENDIX
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APPENDIX A: IRB EXEMPT DETERMINATION LETTER
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APPENDIX B: DEMOGRAPHICS QUESTIONNAIRE
Start of Block: Demographics

D1 Month of your birth?
▼ January (1) ... December (12)

D3 Year of your birth
▼ 1995 (1) ... 2002 (8)

D4 Are you between the age of 18 and 25?

o Yes (1)
o No (2)

D5 What is your gender identity?

o Male (1)
o Female (2)
o Other (3) ________________________________________________
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D6 What is your biological sex?

o Male (1)
o Female (2)
D7 What is your racial or ethnic identification? (fill in all that apply)

▢
▢
▢
▢
▢
▢
▢
▢

American Indian or other Native American (1)
Asian or Pacific Islander (2)
Black or African American (3)
Caucasian (other than Hispanic) (4)
Mexican-American (5)
Puerto Rican (6)
Other Hispanic (7)
Other (8)
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D8 What is your marital status?

o Not married (1)
o Married (2)
o Divorced (3)
o Separated (4)
o Widowed (5)
D9 What is your classification in college?

o Freshman/first-year (1)
o Sophomore (2)
o Junior (3)
o Senior (4)
o Graduate Student (5)
o Unclassified (6)
End of Block: Demographics
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APPENDIX C: PHYSIOLOGICAL PROFILE QUESTIONNAIRE
Start of Block: Physiological Profile

P1 How tall are you?

Feet
▼ 4 Ft (4) ... 7 Ft (7)

P2 Inches
▼ 0 (0) ... 11 (11)

P3 How much do you weigh, in pounds (lbs)?
If you have a scale, go ahead and weigh yourself.
________________________________________________________________

P4 Are you currently pregnant?

o Yes (1)
o No (2)
Skip To: End of Survey If Are you currently pregnant? = Yes
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P5 When was the date of the start of your last period? Be as accurate as possible.
Month (1)

▼ January (1) ... Click to write Scale Point 31 (31)

Day (2)

▼ January (1) ... Click to write Scale Point 31 (31)

Year (3)

▼ January (1) ... Click to write Scale Point 31 (31)

P6 What was the date of the end of your last period? Be as accurate as possible.
Month (1)

▼ January (1) ... Click to write Scale Point 31 (31)

Day (2)

▼ January (1) ... Click to write Scale Point 31 (31)

Year (3)

▼ January (1) ... Click to write Scale Point 31 (31)

P7 How many days ago did your most recent period start?
▼ 0 (0) ... Other (100)

P8 If your previous answer was "Other", write in the number of days since your most recent
period started.
________________________________________________________________
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P9 For the past 6 months, has your period been regular?

o Yes (1)
o No (2)

P10 Are you currently on any birth control method?

o Pill (1)
o IUD (2)
o Shot (3)
o Implant (4)
o Spermicide (5)
o Patch (6)
o I am not on any birth control (7)
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P11 Are you receiving medical treatment for any of the following? Select all that apply.

▢
▢
▢
▢
▢
▢
▢
▢
▢
▢
▢
▢

Ulcerative Colitis (1)
Irritable Bowel Syndrome (IBS) (2)
Gastritis (3)
Crohn's Disease (4)
Stomach Ulcers (5)
Inflamatory Bowel Disease (6)
Functional Dyspepsia (7)
Premenstrual Syndrome (PMS) (8)
Dysmenorrhea (9)
Amenorrhea (10)
Menorrhagia (11)
Other (12) ________________________________________________

P12 Do you experience gastrointestinal symptoms when you are on your period?

o Yes (1)
o No (2)
Skip To: P14 If Do you experience gastrointestinal symptoms when you are on your period? = No
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P13 If yes, can you describe the symptoms you experience? (ex. belly pain, nausea, constipation)

________________________________________________________________
________________________________________________________________

P14
Do you experience gastrointestinal symptoms when you are NOT on your period?

o Yes (1)
o No (2)
Skip To: End of Block If Do you experience gastrointestinal symptoms when you are NOT on your period? = No

P15 If yes, can you describe the symptoms you experience? (ex. belly pain, nausea, constipation)
________________________________________________________________
________________________________________________________________

P16 When in the menstrual cycle do you experience gastrointestinal symptoms?

o 1 week before my period (1)
o 1 week after my period (2)
o 2 weeks after my period (3)
44

P17 Click to write the question text
0

40

How many days BEFORE your period do you
experience these symptoms? ()
How many days AFTER your period do you
experience symptoms? ()

End of Block: Physiological Profile
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